Coming Soon
natera Empower™ Hereditary Cancer Test Coming soon to Peek-A-Boo Baby RGV
Start a HIPAA Compliant Chat with our cancer screening specialist

Does cancer run in your family?

Empower™ is a genetic test that screens genes linked to more than 12 types of hereditary cancer — coming soon to Peek-A-Boo Baby RGV in McAllen.

Blood or saliva sample Results in about 2 weeks 12+ hereditary cancers
Empower Hereditary Cancer Test collection kit
Empower™ collection kit

Should you get tested?

These are the patterns that most often point to an inherited cancer risk. Check any that apply to you or your family.

DNA double helix illustration representing hereditary cancer screening
Hereditary Cancer

EMPOWER — Hereditary Cancer Test

Ages 25+ · blood or saliva
$50+
  • Anyone 25 years or older can test
  • Results in about 2 weeks
  • Cancer specialists available before & after testing
  • Insurance accepted if you’re a candidate
Book This →

Insurance & Coverage

Medicaid covers this test in full for patients who meet the medical criteria for hereditary cancer testing — which is what the checklist above helps determine.

Most other insurance plans cover part of the cost. Natera is in-network with most plans and bills your insurance directly — the majority of in-network patients end up with no out-of-pocket cost at all.

Payment plans are available, interest free. If you do owe something, you can pay it over time rather than all at once. Natera also offers financial assistance that can bring the cost down to $149 or less for households that qualify.

Coverage depends on your plan and on meeting testing criteria, and some plans require prior authorization. Billing and payment plans are handled by Natera. We'll go over what to expect before anything is ordered.

Empower™ and Natera™ are trademarks of Natera, Inc. Peek-A-Boo Baby RGV is an independent provider and is not owned by, affiliated with, or endorsed by Natera, Inc. Empower™ is available by physician order only. This page is general information, not medical advice.